News
Company News: BellaSeno’s Design and Manufacturing Processes Fully ISO 13485 Certified
– Company transitions from research to manufacturing stage, raises an additional EUR 1 million to conduct clinical trial
– Among the first medtech companies worldwide to offer integrated contract manufacturing of additively produced implants under ISO standards
BellaSeno GmbH, a company developing absorbable implants using additive manufacturing technology, today announced it obtained full ISO 13485 certification for its design and additive manufacturing processes, ranging from the concept and prototype to the production of novel, non-silicone-based absorbable implants. Read more…
Company News: Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing
— Patent broadly covers genetic biomarkers and biomarker combinations indicating antibiotic resistance
— First of eleven similar patents filed covering various pathogen/drug combinations
— Strengthens unique position of ARESdb, Ares Genetics’ knowledgebase of antimicrobial resistance genetics
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its wholly owned subsidiary Ares Genetics GmbH has received a notification by the European Patent Office (EPO) on the decision to grant the European Patent No. 3 099 813 titled “Genetic Resistance Testing”. Read more…
Company News: Curetis To Attend Key Conferences in the Third Quarter of 2019
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that the Company will be attending several key conferences in the third quarter of 2019.
Company News: Curetis Reports Results of the Annual General Meeting Held on June 27, 2019
– All proposed AGM resolutions approved by shareholders